14 results
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
of therapy is growing as a result of demographic change. Certain cost containment measures in Europe and the U.S. risk limiting access to innovation … in the pharmaceutical and biotechnology industry are influenced by a variety of factors. Global demographic changes, medical advances, and the desire to improve
6-K
EX-99.1
MOR
Morphosys AG
13 Mar 24
Current report (foreign)
4:08pm
. The need for new forms of therapy is growing as a result of demographic change. Certain cost containment measures in Europe and the U.S. risk … and opportunities in the pharmaceutical and biotechnology industry are influenced by a variety of factors. Global demographic changes, medical advances
6-K
EX-99.1
MOR
Morphosys AG
23 Mar 22
Current report (foreign)
4:15pm
was observed with pelabresib, irrespective of baseline risk status or demographic and disease characteristics. Central pathology review of 27 1L patient bone … is a political goal in many countries. The need for new forms of therapy is growing as a result of demographic change. Certain cost containment measures in Europe
6-K
EX-99.1
u7c4t9s557k5s1mkswm
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
6-K
EX-99.1
iyv1dp
23 Mar 21
Current report (foreign)
3:53pm
6-K
EX-99.1
7xcw auna1aedy
27 Mar 20
Current report (foreign)
3:29pm
6-K
EX-99.1
qqg9 qw8f2mmdh4j
20 Mar 20
Current report (foreign)
2:15pm
6-K
EX-99.1
ocbkjhjir2nwzeu
21 Mar 19
Current report (foreign)
6:14am
6-K
EX-99.1
nfxz0i3r
15 Mar 19
2018 annual report Morphosys Engineering the Medicines of Tomorrow
6:27am
20-F
pve wcxb5u8nw8en
13 Mar 19
Annual report (foreign)
5:13pm
- Prev
- 1
- Next